IDiyas

For the Inventor, By the Inventor

North Andover, MA, United States of America

John E Cochran

USPTO Granted Patents = 33 

 

Average Co-Inventor Count = 3.8

ph-index = 9

Forward Citations = 407(Granted Patents)


Location History:

  • Grandview, WA (US) (1988)
  • Lowell, MA (US) (2003)
  • North Andover, CA (US) (2005)
  • North Andover, MA (US) (2003 - 2012)
  • Marshfield, MA (US) (2003 - 2024)

Company Filing History:

goldMedal31 out of 1,149 
 
Vertex Pharmaceuticals, Inc.
 patents
silverMedal2 out of 832,680 
Other
 patents

Years Active: 1988-2025

Loading Chart...
Loading Chart...
33 patents (USPTO):
1. 12421249 - Inhibitors of APOL1 and methods of using same (2025-09-23),
2. 12122788 - Process of making CFTR modulators (2024-10-22),
3. 11866446 - Inhibitors of APOL1 and methods of using same (2024-01-09),
4. 11584761 - Process of making CFTR modulators (2023-02-21),
5. 8871904 - Processes and intermediates (2014-10-28),
6. 8637457 - Processes and intermediates (2014-01-28),
7. 8399615 - Processes and intermediates (2013-03-19),
8. 8338412 - Inhibitors of P38 (2012-12-25),
9. 7951809 - Inhibitors of p38 (2011-05-31),
10. 7919513 - Inhibitors of p38 (2011-04-05),
11. 7776887 - Processes and intermediates (2010-08-17),
12. 7598277 - Inhibitors of p38 (2009-10-06),
13. 7488727 - Thiazole compounds useful as inhibitors of protein kinase (2009-02-10),
14. 7423049 - Inhibitors of p38 (2008-09-09),
15. 7365072 - Inhibitors of p38 (2008-04-29),

Title: John E Cochran: A Pioneer in Pharmaceutical Innovations

Introduction

John E Cochran, based in North Andover, MA, is a distinguished inventor with a remarkable portfolio of 32 patents. His innovative contributions primarily focus on the pharmaceutical field, specifically addressing critical health issues through novel compounds and methodologies.

Latest Patents

Among his latest patents, Cochran has developed processes for synthesizing CFTR modulators. This significant work outlines methods for creating Compound I and its pharmaceutically acceptable salts. Additionally, he has contributed to the invention of inhibitors of APOL1. His disclosures include compounds of Formula I, their tautomers, deuterated derivatives, and compositions aimed at treating APOL1-mediated diseases such as pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and non-diabetic kidney disease (NDKD).

Career Highlights

Cochran's career includes meaningful tenures at Vertex Pharmaceuticals, Inc., where he played a crucial role in advancing drug development. His innovative work has not only garnered patents but has also significantly impacted the pharmaceutical landscape by addressing complex diseases.

Collaborations

Throughout his career, Cochran has collaborated with notable professionals, such as Guy W Bemis and Francesco Gerald Salituro. These partnerships have fostered a collaborative spirit that has been instrumental in driving research and development efforts in the pharmaceutical industry.

Conclusion

John E Cochran's extensive patent portfolio and collaborative efforts underline his dedication to innovative solutions in medicine. His work continues to pave the way for advancements in the treatment of serious health conditions, making him a prominent figure in the realm of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…